| Old Articles: <Older 1011-1020 Newer> |
|---|
 |
Fast Company
February 2004 |
Pot Proponent Just Says No Medical marijuana's elder statesman is not convinced that the therapeutic benefits of cannabis can be separated from the psychoactive effects -- or that cannabis should be "pharmaceuticalized."   |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
Insurance & Technology
February 7, 2004
Katherine Burger |
Father Knows Best The author's father, who volunteers in a community center to help seniors file and follow up on insurance claims, airs some gripes with the medical insurance industry's lack of standardization. |
Insurance & Technology
February 7, 2004
Julie Gallagher |
Taking a New Look at HSAs Self-service tools support newly authorized health savings accounts |
BusinessWeek
February 16, 2004
Balfour & Kripalani |
Over The Sea, Then Under The Knife Patients worldwide are heading to hospitals in Asia for affordable, high-quality surgery. |
The Motley Fool
February 9, 2004
Alyce Lomax |
High Hopes for Andrx Are hopeful investors jumping the gun on the drug maker's generic prospects? |
Wired
February 2004
Brian Alexander |
John Sperling Wants You to Live Forever He founded the University of Phoenix. He also cloned a pet cat. His latest iconoclastic quest: Research, develop, and sell the new science of longevity. |
The Motley Fool
February 4, 2004
J. Graham |
Sanofi's Aggressive for Aventis The drug company wants larger rival Aventis any way it can get it. |
The Motley Fool
February 3, 2004
David Nierengarten |
Big Break for a Small Biotech? Axonyx's new drug for Alzheimer's disease could be first in its class. |
The Motley Fool
February 2, 2004
Alyce Lomax |
Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent. |
| <Older 1011-1020 Newer> Return to current articles. |
